```html

Junin Virus Hemorrhagic Fever – A Comprehensive Medical Guide

Overview

Junin virus hemorrhagic fever, also called Argentine hemorrhagic fever (AHF), is a severe, acute viral disease caused by the Junin arenavirus. The virus belongs to the family Orthomyxoviridae and is transmitted to humans primarily through contact with contaminated rodent excreta. The disease is endemic to the Gran Chaco region of Argentina, where it accounts for an estimated 5,000–6,000 cases per year, although exact numbers vary because many infections are mild or go unreported.

The illness affects people of all ages but is most common in agricultural workers, ranchers, and residents of rural communities where the primary rodent host, Calomys musculinus (the “field mouse”), lives in close proximity to homes. Before the development of an effective vaccine in the 1990s, mortality rates ranged from 15–30 %. Today, with early diagnosis, ribavirin therapy, and supportive care, the case‑fatality rate has dropped to ~5 %.

Symptoms

Symptoms appear after an incubation period of 7–14 days and progress through three clinical phases: prodromal, neurologic (or “hemorrhagic”), and convalescent.

Prodromal Phase (Days 1‑5)

• Fever – often > 38.5 °C (101.3 °F), sudden onset.
• Headache – throbbing, may be accompanied by photophobia.
• Myalgia – generalized muscle aches, especially in the calf and back.
• Arthralgia – joint pain, commonly in knees and elbows.
• Fatigue & malaise – profound tiredness.
• Nausea, vomiting, & abdominal pain.
• Rash – maculopapular, typically on trunk and extremities.

Neurologic / Hemorrhagic Phase (Days 6‑10)

• Bleeding tendencies – petechiae, ecchymoses, epistaxis, gingival bleeding.
• High‑grade fever persisting or spiking.
• Confusion, delirium, or encephalitis – occasional seizures.
• Hepatomegaly & splenomegaly – enlarged liver and spleen palpable.
• Elevated liver enzymes (AST, ALT) and bilirubin.
• Renal dysfunction – oliguria or proteinuria.
• Cardiovascular signs – tachycardia, hypotension, possible shock.

Convalescent Phase (Weeks 2‑4)

• Gradual resolution of fever and bleeding.
• Persistent fatigue and weakness lasting up to 6 weeks.
• Possible neurological sequelae: hearing loss, tremor, or mild cognitive deficits.

Causes and Risk Factors

Cause

Junin virus is an RNA virus transmitted to humans primarily by inhalation of aerosolized particles from the urine, droppings, or saliva of infected rodents. Direct contact with broken skin or mucous membranes can also lead to infection. Human‑to‑human transmission is rare but has been documented via blood transfusion, organ transplantation, or needlestick injuries.

Risk Factors

• Living or working in the Gran Chaco region of Argentina (provinces: Buenos Aires, Córdoba, Corrientes, Formosa, La Pampa, Mendoza, Santa Fe, and Santiago del Estero).
• Occupations with frequent rodent exposure – farmers, ranch hands, grain store workers, and housekeepers.
• Poor housing conditions that allow rodents to enter living spaces.
• Seasonality – incidence peaks during the warm, dry months (October–April) when rodent activity is highest.
• Immunocompromised individuals may experience more severe disease.

Diagnosis

Because early symptoms mimic many other febrile illnesses (influenza, dengue, leptospirosis), laboratory confirmation is essential.

Clinical Evaluation

• Detailed travel and exposure history (especially recent rodent contact).
• Physical exam focusing on rash, bleeding sites, hepatosplenomegaly, and neurologic status.

Laboratory Tests

• Serology – detection of IgM antibodies against Junin virus (ELISA). IgM appears ~7 days after symptom onset.
• Reverse transcription polymerase chain reaction (RT‑PCR) – identifies viral RNA in blood, serum, or cerebrospinal fluid; useful during the first week.
• Virus isolation – performed in biosafety level‑3 (BSL‑3) labs; rarely needed for routine diagnosis.
• Supportive labs: complete blood count (CBC) (often shows leukopenia, thrombocytopenia), liver function tests (elevated AST/ALT), renal panel, coagulation profile (prolonged PT/PTT).

Imaging

• Chest X‑ray – may reveal interstitial infiltrates if pulmonary edema develops.
• Abdominal ultrasound – evaluates liver and spleen size.

Sources: WHO, CDC, Mayo Clinic, “Arenavirus infections” – *Lancet Infectious Diseases* 2021.

Treatment Options

There is no specific antiviral cure, but early therapy markedly reduces mortality.

Antiviral Therapy

• Ribavirin – a nucleoside analog; administered intravenously (30 mg/kg loading dose, then 15 mg/kg every 6 h for 4 days, followed by 7.5 mg/kg every 8 h for 4 days). Initiated within 7 days of symptom onset yields the best outcomes (mortality ↓ from ~15 % to ~5 %).

Supportive Care

• Fluid management – isotonic crystalloids to maintain euvolemia; monitor for pulmonary edema.
• Blood product transfusion – platelets, fresh‑frozen plasma, or packed red cells for significant hemorrhage or coagulopathy.
• Renal support – diuretics or dialysis if acute kidney injury develops.
• Neurologic monitoring – seizure prophylaxis (e.g., levetiracetam) if encephalitis suspected.

Vaccination

A live‑attenuated vaccine (Candid#1) was introduced in Argentina in 1990 and has demonstrated > 95 % efficacy. It is recommended for persons living in endemic areas and for laboratory workers handling arenaviruses. The vaccine is not widely available outside Argentina.

Lifestyle & Adjunctive Measures

• Rest and gradual return to activity after fever resolves.
• Balanced nutrition and adequate hydration.
• Avoid non‑steroidal anti‑inflammatory drugs (NSAIDs) during the hemorrhagic phase because of increased bleeding risk.

Living with Junin Virus Hemorrhagic Fever

Most patients recover fully within 1–2 months, but the convalescent period may be physically and emotionally taxing. Below are practical tips for a smoother recovery.

Daily Management

• Hydration – aim for 2–3 L of fluid per day unless fluid restriction is ordered.
• Nutrition – high‑protein, low‑fat meals; consider oral nutrition supplements if appetite is poor.
• Rest – schedule 10–12 hours of sleep/nightly; incorporate short naps if needed.
• Medication adherence – complete the full ribavirin course and any prescribed supportive meds.
• Monitor vitals – temperature, heart rate, blood pressure, and urine output at home (write them down). Report significant changes to your clinician.
• Psychological support – counseling or support groups can help with anxiety and post‑viral fatigue.

Follow‑up Care

• Clinic visit 1 week after discharge for CBC, liver and renal panels.
• Monthly labs for 3 months to ensure complete resolution of organ dysfunction.
• Neuro‑exam at 6 weeks if any confusion, headache, or hearing changes persisted.

Prevention

Because there is no universal vaccine outside Argentina, prevention hinges on reducing rodent exposure and implementing infection‑control measures.

Environmental Control

• Seal cracks and openings in homes; use metal screens on windows and doors.
• Store grain, food, and waste in rodent‑proof containers.
• Keep yards clean—remove debris, tall grass, and piles of wood where rodents shelter.
• Use rodent traps or integrated pest‑management programs; avoid rodenticides indoors without professional guidance.

Personal Protective Measures

• Wear thick gloves and a N95/FFP2 mask when cleaning rodent‑infested areas.
• Wash hands thoroughly with soap and water after handling animals or soil.
• Disinfect surfaces with a 1 % bleach solution or 70 % ethanol after any rodent contact.

Travel & Occupational Advice

• Travelers to endemic regions should inquire about vaccination in Argentina.
• Laboratory personnel must follow BSL‑3 containment for virus culture and handle specimens with universal precautions.
• Healthcare workers should use standard infection‑control practices; post‑exposure prophylaxis with ribavirin is considered for needlestick injuries involving suspected Junin samples.

Complications

If diagnosis is delayed or treatment is inadequate, several serious complications can arise:

• Severe hemorrhage – gastrointestinal, pulmonary, or intracranial bleeding.
• Acute respiratory distress syndrome (ARDS) – secondary to pulmonary edema.
• Acute kidney injury – may require temporary dialysis.
• Hepatic failure – jaundice, coagulopathy, encephalopathy.
• Neurologic sequelae – persistent hearing loss, tremor, or cognitive impairment.
• Secondary bacterial infections – especially pneumonia or urinary tract infection.
• Chronic fatigue syndrome‑like picture lasting months after viral clearance.

When to Seek Emergency Care

Sources: WHO Fact Sheet on Argentine Hemorrhagic Fever (2022); CDC Arboviral Diseases (2023); Mayo Clinic – Junin Virus (2021); Cleveland Clinic – Viral Hemorrhagic Fevers (2022); Pérez‑Molina, J. “Junin Virus Infection” *Lancet Infect Dis* 2021; NIH ClinicalTrials.gov (ribavirin studies, 2020‑2024).

```